Metsera, Inc. (NASDAQ:MTSR) reported encouraging Phase 1 results for MET-233i, its once-monthly amylin analog, which showed a mean weight loss of up to 8.4% at Day 36 after subtracting the placebo.

Metsera, Inc. (NASDAQ:MTSR) is one of the 11 Hot New Stocks to Invest in Now. On June 22, Metsera, Inc. (NASDAQ:MTSR) presented at the 85th Scientific Sessions of the American Diabetes Association ...

Metsera showed 0% earnings growth in its most recent report, while sales growth came in at 0%. Metsera earns the No. 177 rank among its peers in the Medical-Biomed/Biotech industry group.

VESPER-1 and interim VESPER-3 data release expected in September 2025; Phase 3 initiation on track for late 2025 MET-233i (once-monthly amylin analog) delivered class-leading Phase 1 results including ...

--Metsera, Inc., a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, today reported fourth quarter and full year 2024 ...

Metsera will present significant clinical data from its Phase 1/2 trial of MET-097i, a next-generation GLP-1 receptor agonist, at a prominent scientific conference, enhancing the company's ...

View Metsera, Inc. MTSR stock quote prices, financial information, real-time forecasts, and company news from CNN.

Metsera, a biotech focused on obesity drugs that came out of stealth this year, said Tuesday that it is partnering with drug manufacturer Amneal Pharmaceuticals to produce injectable and oral ...

Metsera’s obesity drug candidate targeting the amylin hormone showed marked efficacy in an early trial and the potential to have longer-lasting effects than current weight loss treatments ...

Metsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to ...